Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library.
Introduction
Endocytic membrane trafficking plays an essential role in delivering membrane components, receptor-associated ligands, extracellular fluid and pericellular solute molecules inside the cell. Three major categories of endocytic processes have been described: phagocytosis, receptor-mediated endocytosis and pinocytosis (Bohdanowicz and Grinstein, 2013) . These internalization processes can be distinguished by the size of the vesicle formed, the physical characteristics of the cargo and the endocytic machineries involved. Macropinocytosis (also known as fluid-phase endocytosis or cell drinking) is distinct in many ways from the better characterized receptormediated endocytosis and phagocytosis. Macropinocytotic internalization of pericellular solutes does not require physical interaction with the plasma membrane (i.e. receptor binding), while phagocytosis and receptor-mediated endocytosis are ligand-receptor-driven processes (Mercer and Helenius, 2009) . Phagocytosis (solid-phase endocytosis or cell eating) requires localized and transient remodelling of actin filaments, resulting in a coherent growth of the plasma membrane around the particle, formation of the phagosome and particle internalization (Botelho et al., 2000) . Receptormediated endocytosis is largely an actin-independent process stimulated by specific cell-surface receptors, such as C-type lectin receptors, Fcγ and Fcε and subsequent translocation of adaptor proteins to the plasma membrane (Berry and Call, 2017) . In contrast to phagocytosis and receptor-mediated endocytosis, macropinocytosis is initiated by extensive, submembranous activation of the actin cytoskeleton resulting in plasma membrane ruffling over the entire dorsal surface of the cell or the cellular periphery (Grimmer et al., 2002; Bohdanowicz and Grinstein, 2013) . Membrane ruffles adhere to the non-extended plasma membrane or circularize, fuse on the lateral side and close, resulting in a massive internalization of extracellular fluid (up to 40% of the cell volume h À1 ; Sallusto et al., 1995; Norbury, 2006) and associated solutes into heterogeneous vacuoles (0.2-5 μm), called macropinosomes (Chung et al., 2015) . Macropinocytosis can be induced in many cell types upon stimulation with phorbol esters, cytokines and growth factors (Nakase et al., 2015; Ghoshal et al., 2017) . Consistent with this statement, an increased rate of solute macropinocytosis has been shown to facilitate phenotypic and functional changes in a wide variety of cell types and contribute to the development of various pathological processes. For instance, internalization of extracellular proteins through macropinocytosis is utilized by cancer cells to support their unique metabolic needs, leading to increased cancer cell proliferation in vitro and tumour growth in vivo (Commisso et al., 2013) . Vaccinia, adeno, picorna and other virus families and several types of bacteria, including Shigella, Mycobacterium, Salmonella and Legionella, 'learnt' how to stimulate membrane ruffling and invade host cells via macropinocytosis (Mercer and Helenius, 2009; Lim and Gleeson, 2011) . Renal tubular cells internalize calcium oxalate monohydrate crystals via macropinocytosis, a process that may contribute to nephrolithiasis (Kanlaya et al., 2013) . Macropinocytosis of amyloid precursor protein in neuronal cells has been implicated in the pathogenesis of Alzheimer's disease (Tang et al., 2015) . Evidence has also been accumulating that macrophages internalize exogenous lipids via macropinocytosis, leading to foam cell formation, a key pathological event in the initiation and progression of atherosclerosis (Kruth et al., 2005; Csanyi et al., 2017) . Despite this information, no clinically useful inhibitors of macropinocytosis are available to inhibit macropinocytosis in pathological processes.
The currently available pharmacological tools to inhibit macropinocytosis are limited and comprise (i) actin polymerization inhibitors (Aleksandrowicz et al., 2011) , (ii) PI3K blockers (Araki et al., 1996) and (iii) inhibitors of sodium/ hydrogen exchangers (NHEs) (Koivusalo et al., 2010) . The actin perturbant cytochalasin D and latrunculins have been shown to inhibit membrane ruffling and macropinocytosis. However, they also block phagocytosis and all other cellular processes involving actin polymerization (Stockinger et al., 2006) . The PI3K inhibitor wortmannin and LY290042 block macropinocytosis and phagocytosis in macrophages, fibroblasts and epithelial cells (Ivanov, 2008) . As PI3K is an upstream mediator of Akt, mTOR and NOS and known to regulate signalling processes downstream of glucose and amino acid uptake (Kohn et al., 1996) , wortmannin and LY290042 are expected to inhibit many cellular processes in addition to macropinocytosis. The epithelial sodium channel blocker amiloride inhibits both constitutive and stimulated macropinocytosis and also phagocytosis in a variety of mammalian cells (Ivanov, 2008; Zhang et al., 2015) . Currently, the selective NHE blocker ethyl-isopropyl amiloride (EIPA) and dimethyl amiloride are considered to be the first choices for pharmacological inhibition of macropinocytosis (Ivanov, 2008) . However, possible endocytosis-unrelated effects of these drugs on ion transport, intracellular pH and cytoskeleton limit their use as pharmacological inhibitors of macropinocytosis.
Considering these limitations in the field of endocytosis, the goal of the present study was to perform a systematic screen of a wide range of FDA-approved drugs to identify new, clinically relevant inhibitors of macropinocytosis. One of the most effective strategies for drug development is the repurposing of existing drugs that have been approved by the FDA for human therapy (Ashburn and Thor, 2004) . The key advantage of drug repurposing is that the drugs have already undergone extensive safety and bioavailability testing and thus allow more rapid clinical development at a lower cost compared with de novo drug development. FDAapproved drug libraries provide rich sources of bioactive agents that have been carefully selected to maximize chemical and pharmacological diversity. In the present study, we first optimized a cell-based macropinocytosis assay for screening purposes. Following optimization, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. The primary screen identified 14 compounds that at~10 μM concentration inhibit >95% of macropinocytotic solute internalization. A series of secondary assays were performed to confirm inhibitory activity, determine IC 50 values and investigate cell toxicity. To investigate selectivity, we tested whether the candidate compounds inhibit phagocytosis, caveolae-dependent endocytosis and clathrin-mediated endocytosis. We identified one compound that potently (IC 50 = 131 nM) inhibit macropinocytosis, without exerting cytotoxic effects or inhibiting other endocytic pathways. Finally, the ability of the identified compound to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages, was confirmed.
Methods

Animals
All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC), Augusta University, Augusta, USA. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Every effort was made to minimize animal suffering and to reduce the number of animals used. Eight-to ten-week-old male, C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed at controlled temperatures (21-23°C) with ad libitum access to standard rodent chow and water and 12 h light-dark cycles. Mice were anaesthetized (isoflurane inhalation, 3%) and killed by cervical dislocation and exsanguinated. The mice were nonblindly randomized prior to tissue isolation. (2 ng·mL À1 , 6 days) as previously described (Thomas and Lipsky, 1996; Potts et al., 2008) .
Flow cytometry
Flow cytometry experiments were performed using the Becton Dickinson (Franklin Lakes, NJ, USA) FACSCalibur flow cytometer using a standard protocol . Figure 1B . ; caveolin-mediated endocytosis) was investigated in RAW 264.7 macrophages following their incubation with vehicle (negative control), candidate drugs (IC 100 concentration, 1 h) or positive controls for clathrin-mediated (chlorpromazine, 10 μM, 1 h) and caveolin-mediated endocytosis (nystatin, 10 μM, 1 h). Fluorescence intensity was measured using the FL1 channel for FITC and Alexa Fluor 488 (Ex: 488 nm; Em: 530 nm).
Phagocytosis assay
Phagocytosis was investigated using the CytoSelect™ 96-Well Phagocytosis Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, RAW 264.7 macrophages were plated in 96-well plates at a density of 0.5 × 10 6 cells mL À1 . Cells were pretreated with vehicle (negative control), selected macropinocytosis inhibitors (IC 100 concentration, 1 h) and cytochalasin D (2 μM, 1 h) and then incubated with enzyme-labelled, Escherichia coli particles (10 μL per well) for 6 h. Adherent cells were fixed with 3.2% buffered formaldehyde solution and blocked for 30 min at room temperature on an orbital shaker. After permeabilization, the substrate solution was added, and the mixture was incubated for 30 min at room temperature. The reaction was stopped, and absorbance was read at 450 nm using a Clariostar Monochromator Microplate Reader (BMG Labtech, Cary, NC, USA).
Cytotoxicity assay
Cytotoxicity was investigated using the Thermo Fisher LDH Cytotoxicity Assay Kit according to the manufacturer's instructions.
Imaging experiments
Confocal microscopy. Following treatment, macrophages were fixed in 2% PFA, permeabilized with 0.1% Triton X-100 and stained with Alexa Fluor 488 ® phalloidin and 
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Hoechst 33342 (Thermofisher, Grand Island, NY, USA). Images were captured using a Zeiss (San Diego, CA, USA) 780 inverted confocal microscope.
Scanning electron microscopy. Macrophages were fixed (4% PFA, 2% glutaraldehyde in 0.1 M sodium cacodylate solution) overnight at 4°C. Then the cells were dehydrated through a graded ethanol series (25-100%) and washed with 100% ethanol before critical point drying (Tousimis Samdri-790; Tousimis, Rockville, MD, USA). Coverslips were mounted onto aluminium stubs and sputter coated with 3.5 nm of gold/palladium (Anatek USA-Hummer, Union City, CA, USA). Cells were imaged at 20 kV using a Philips XL30 scanning electron microscope (FEI, Hillsboro, OR, USA).
Determination of NHE-1 activity
Activity of NHE was determined as described previously using the dual-excitation ratiometric pH indicator, acetoxymethyl ester of 29,79-bis(carboxyethyl)-5(6)-carboxyfluorescein (BCECF-AM) (Molecular Probes, Inc., Eugene, OR, USA) (Swanson et al., 1998) . Briefly, RAW 264.7 macrophages were grown on glass coverslips in DMEM with 10% FBS and growth arrested at 70-80% confluence by incubation in DMEM with 1% FBS for 24 h. Cells were pre-incubated with vehicle, EIPA (positive control; 25 μM) or imipramine (5 μM) for 60 min and then loaded with BCECF-AM (3 mM) for 30 min. Cells were washed twice and incubated in a HEPES-Tris balanced salt solution (130 mM NaCl, 5 mM KCl, 1.5 mM CaCl 2 , 1.0 mM MgCl 2 and 20 mM HEPES; pH 7.4) for 30 min. All subsequent experiments were performed at 25°C. Cells were acid loaded by incubation with HEPES-Tris-buffered salt solution containing 20 mM NH 4 Cl, followed by washing with HEPES-Tris-buffered salt solution without NH 4 Cl. Removal of NH 4 Cl is followed by cytosolic acidification due to NH 3 exit with cytosolic dissociation of NH 4 + and retention of H + .
The rate of pH recovery from acidosis was recorded over the next 10 min. The pH-dependent fluorescent signal of BCECF-AM was obtained by illuminating the samples at excitation wavelengths of 490 and 440 nm using a Nikon (Melville, NY, USA) TE2000 inverted microscope. The ratio of signals obtained at 490 and 440 nm wavelengths was used to monitor changes in intracellular pH. The contribution of NHE to pH recovery was confirmed by treatment with EIPA.
Western blot
Western blotting was performed as previously described using the Odyssey CLx Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE, USA) (Csanyi et al., 2012) . Briefly, protein concentration was estimated using the bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL, USA), according to manufacturer's instructions. Equal amounts of protein (30 μg) were heated in Laemmli sample buffer (BioRad Laboratories, Inc., Hercules, CA, USA) at 95°C for 5 min, separated on SDS-PAGE gels, transferred onto nitrocellulose membranes (Li-Cor Biosciences) and probed with the following primary antibodies: MEK, p-MEK, ERK, P-ERK, PKCδ, p-PKCδ and β-tubulin (Cell Signaling, Danvers, MA, USA; rabbit, 1:1000). The IRDye-conjugated secondary antibodies (Li-Cor Biosciences) were used to detect the primary antibodies.
PI3K activity
PI3K activity was measured using the Echelon's PI3-Kinase Activity ELISA: Pico kit (Echelon Biosciences).
ROS measurement
L-012, a luminol-based chemiluminescent probe, was used to determine O 2 ·À generation as described previously 
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . All data are expressed as means ± SEM. Statistical analysis was performed using GraphPad Prism 7 (La Jolla, CA, USA). One-way ANOVA, followed by a Bonferroni post hoc test, was used to analyse statistical differences. A P-value less than 0.05 was considered statistically significant. 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c,d,e) .
Results
Primary and secondary screens
In order to identify chemical compounds that inhibit macropinocytosis, we performed a systemic screen of the Screen-Well™ FDA Approved Drug Library (Enzo Life Sciences), which contains 640 structurally and pharmacologically diverse FDA-approved drugs. An acceptable inhibitor would inhibit macropinocytosis at low concentrations but lack inhibitory activity against phagocytosis and receptormediated endocytosis. Schematic representation of the screening strategy to identify such compounds is shown in Figure 1A . Accordingly, we first optimized a cell-based assay using RAW 264.7 macrophages incubated with FITC-dextran (70 000 MW, 150 μg·mL À1 ) and PMA (1 μM; macropinocytosis stimulator), with or without EIPA (25 μM; macropinocytosis inhibitor) as a detection system for macropinocytosis ( Figure 1B ). FITC-dextran macropinocytosis was quantified in live cells identified by the Live/Dead™ Fixable Far Red dye ( Figure 1B, C) . Following optimization, a primary screen using a 1-10 μM final compound concentration to identify compounds capable of inhibiting macropinocytosis was performed. In each plate, row 1, column 1 contained no compounds and no FITC-dextran; row 1, column 2 contained only FITC-dextran; row 1, column 3 contained FITC-dextran and PMA; and row 1, column 4 contained FITC-dextran, EIPA (60 min pre-incubation) and PMA. FDA-approved compounds were administered in row 1 through 4. Finally, each plate contained a second set of controls in row 4. The primary screen led to the identification of 14 compounds (hit rate: 2.2%) that inhibit PMA-induced FITC-dextran internalization by more than 95% in RAW 264.7 macrophages ( Figure 1D ). Next, a series of secondary experiments were performed to confirm inhibitory activities of identified compounds. Eleven out of 14 drugs (78%) were confirmed to inhibit FITC-dextran internalization (>95%) in response to PMA treatment in RAW 264.7 cells ( Figure 1E ). Of these hits, two compounds were excluded due to incomplete (~70%) inhibition in response to the physiological macropinocytosis stimulator, macrophage colony-stimulating factor (M-CSF) (Yoshida et al., 2009; Ghoshal et al., 2017) (Figure 1F ). Two additional compounds were eliminated from further analysis due to their incomplete inhibition of macropinocytosis in primary mouse macrophages ( Figure 1G ). The primary screen of the library and subsequent secondary analyses identified seven compounds that inhibit stimulated macropinocytosis at low micromolar concentrations in macrophages.
Determination of IC 50 values
Individual serial dilutions of the seven lead compounds (flubendazole, terfenadine, itraconazole, phenoxybenzamine, vinblastine, auranofin and imipramine) at concentrations ranging from 0 to 50 μM (5×) were prepared and incubated with RAW cells (60 min), followed by treatment with FITC-dextran and stimulation with PMA. IC 50 values were calculated from logarithmic scale plots of the inhibitor concentrations against the percentage of inhibitory activity relative to the uninhibited control, using Prism software (GraphPad Software Inc., San Diego, CA, USA). The IC 50 values for flubendazole, terfenadine, itraconazole, phenoxybenzamine, vinblastine, auranofin and imipramine are shown in Figure 2A -G and Table 1 . For all subsequent experiments, the maximal inhibitory concentration (IC 100 ) of identified compounds was used (Table 1) .
Cytotoxicity and selectivity
An undesirable side effect would be the reduction of solute internalization in the assays due to cell death following longer drug exposure rather than a direct inhibition of macropinocytosis. To verify that this was not the case for the identified compounds, the 50% cytotoxic concentration (CC 50 ) values of identified inhibitors were determined using a commercially available LDH cytotoxicity kit (Thermo Fisher). This assay quantitatively measures LDH released into the media due to compromised plasma membrane integrity (i.e. dead cells). The CC 50 values were calculated from logarithmic scale plots of the inhibitor concentrations against the percentage of cytotoxic activity, using Prism software ( Table 1 ). The calculated selectivity indexes (SI = CC 50 /IC 50 ) are shown in Table 1 . As shown in Figure 3A , flubendazole treatment (9 μM, 24 h) induced LDH release (~31.5% of the positive control, lysis solution) following a longer exposure. Due to its lower selectivity index (SI = 14.2), flubendazole was excluded from further analysis.
As mentioned, an acceptable macropinocytosis inhibitor would not only block macropinocytosis but also should be inactive against other endocytic processes. Of the six remaining compounds, none inhibited clathrin-mediated endocytosis ( Figure 3B ). Chlorpromazine, a known inhibitor of clathrinmediated endocytosis (Subtil et al., 1994) , blocked~90% of FITC-transferrin uptake, thus validating the assay. Only terfenadine was found to moderately (~10%) inhibit caveolin-mediated endocytosis ( Figure 3C ). In these experiments, the caveolin-mediated endocytosis inhibitor nystatin was used as a positive control (Zhu et al., 2011 ). Next, we tested the effect of identified macropinocytosis inhibitors on phagocytosis using the CytoSelect™ Phagocytosis Assay (Cell Biolabs), which utilizes enzyme-labelled E. coli particles as a phagocytosis pathogen. Cytochalasin D, a known inhibitor of actin polymerization and phagocytosis (Ting-Beall et al., 1995) , was used as a positive control. Our results demonstrated that three of six drugs (auranofin, itraconazole and terfenadine) inhibited phagocytosis by greater than or equal to 20% ( Figure 3D ). The relatively high inhibitory rate (50%) can be explained by the fact that both macropinocytosis and phagocytosis use the cytoskeleton to extend membrane protrusions and they share several regulatory signalling molecules (Mercer and Helenius, 2009) . Taken together, the secondary toxicity and specificity screens identified three macropinocytosis inhibitors (imipramine, phenoxybenzamine and vinblastine) that exert no cytotoxic effects at IC 100 concentrations after a longer exposure and lack inhibitory activities against phagocytosis and clathrinmediated and caveolin-mediated endocytosis. The microtubule inhibitor vinblastine was removed from further analysis as it inhibits important physiological processes, such as cell cycle, and has serious undesired side effects in vivo (Cariou et al., 2010) .
Imipramine inhibits plasma membrane ruffle formation, a critical early step in macropinocytosis
Plasma membrane activities during macropinocytosis can be divided into four consecutive steps: (i) membrane ruffling, (ii) cup formation, (iii) cup closure and (iv) macropinosome formation/solute internalization. We next used scanning electron microscopy and confocal imaging to investigate which morphological steps were inhibited by imipramine and phenoxybenzamine. The scanning electron microscopy images demonstrated that PMA stimulated membrane ruffling (yellow arrow), ruffle circularization (red arrow) and cup formation (blue arrow) on the dorsal surface of macrophages ( Figure 4A ). Pre-incubation of macrophages with phenoxybenzamine partially (65%) inhibited, while imipramine completely blocked PMA-induced membrane ruffle formation ( Figure 4B) . Interestingly, the remaining ruffles on the surface of phenoxybenzamine-treated macrophages were able to circularize and form cups ( Figure 4A ), suggesting that signalling mediators involved in cup closure and/or macropinosome formation are also inhibited by phenoxybenzamine. Inhibition of PMA-induced membrane ruffling by imipramine was confirmed by confocal laser scanning microscopy ( Figure 4C ).
Imipramine did not inhibit Na + /H + exchanger activity
The NHE blocker EIPA is currently considered as the most effective and selective pharmacological tool to inhibit macropinocytosis (Ivanov, 2008; Commisso et al., 2013) . As NHE is involved in volume and pH regulation and known to regulate the activity of pH sensitive signalling molecules (Pedersen et al., 2007; Hisamitsu et al., 2012) , we next investigated whether imipramine inhibits NHE activity. Intracellular pH (pH i ) and the functional activity of NHE in macrophages were determined using the ratiometric pHsensitive dye, BCECF-AM (Swanson et al., 1998) . As shown in Figure 5A -C, the rate of pH i recovery from an acid load (dpH i / dt) was identical in vehicle-treated and imipramine-treated macrophages. On the other hand, EIPA inhibited the rate of pH i recovery, demonstrating the role of NHE in pH regulation ( Figure 5B, C) . These results suggest that imipramine does not inhibit NHE activity or regulate pH i in macrophages.
Imipramine inhibited ROS signalling but not Ras/MEK/ERK, PKCδ or PI3K activation
Previous studies demonstrated that increased Ras activity stimulates macropinocytosis in both mammalian cells and Dictyostelium (Lim et al., 2002; Palm et al., 2015) and knockdown of Ras leads to an attenuation of macropinocytosis (Commisso et al., 2013) . We therefore investigated the effect of imipramine on the activation of downstream Ras effectors MAPK kinase (MEK) and ERK using Western blotting. PMA treatment rapidly (5 min) stimulated MEK and ERK phosphorylation in macrophages ( Figure 6A-C) . Pretreatment of macrophages with imipramine did not inhibit PMA-induced phosphorylation of MEK and ERK, suggesting that inhibition of Ras/MEK/ERK signalling is not responsible for the inhibitory effect of imipramine on macropinocytosis. PKC activation plays a critical role in macropinocytosis (Singla et al., 2018) . To investigate whether imipramine inhibits PKC activation in macrophages, we measured the phosphorylation status of PKCδ (major PKC isoform in macrophages) following PMA, ±imipramine treatment. Our results demonstrated that imipramine does not inhibit PMA-induced activation of PKCδ (Figure 6A, D) . Pharmacological inhibitors of PI3K (i.e. wortmannin) inhibit macropinocytosis (Palm et al., 2017) . We next investigated whether imipramine inhibits PMA-induced PI3K activity in macrophages using a PI3K activity ELISA kit (Echelon Biosciences). Our results indicated that imipramine does not inhibit PI3K activity ( Figure 6E) .
Our laboratory has recently demonstrated that NADPH oxidase 2 (Nox2)-derived ROS mediate initiation of membrane ruffle formation in response to PMA and M-CSF treatments . As shown in Figure 6F , G, pretreatment of macrophages partially (50%) inhibited PMA-induced ROS formation in macrophages. The specificity of L-012 for superoxide anion (O 2 ·À ) was confirmed by the addition of SOD (150 U·mL À1 ). These data suggest that imipramine may inhibit macropinocytosis through inhibition of redox signalling. Further studies are required to identify the precise mechanism(s) by which imipramine inhibits macropinocytosis.
Imipramine inhibited macropinocytosis in cancer cells, dendritic cells and macrophages
Macropinocytosis has been implicated in a variety of pathological conditions, including cancer (Lim and Gleeson, 2011) , allergic disorders (Sallusto et al., 1995) and atherosclerosis (Kruth et al., 2005) . Cancer cells support their increased metabolic needs by nutrient macropinocytosis, which in turn leads to their increased proliferation in vitro and tumour growth in vivo (Commisso et al., 2013) . As shown in Figure 7 A, pre-incubation of 4T1 mammary carcinoma cells with imipramine inhibited PMA-induced macropinocytosis. Immature dendritic cells internalize antigens via macropinocytosis and present the processed antigenic peptides to T-cells to initiate an adaptive immune response (Sallusto et al., 1995) . Our FACS results demonstrated that PMA-induced antigen (ovalbumin) macropinocytosis was inhibited in CD11c + immature dendritic cells ( Figure 7B ).
Also, macrophages internalize unmodified, native LDL
Figure 4
Imipramine inhibits membrane ruffle formation. (A) RAW 264.7 macrophages were treated with vehicle, PMA (1 μM, 30 min) or pretreated with imipramine (5 μM, 60 min) or phenoxybenzamine (5 μM, 60 min) and then challenged with PMA. Cells were processed for SEM imaging. Membrane ruffles (yellow arrows), circularized C-shaped ruffles (red arrows) and macropinocytotic cups (blue arrows) were observed on the dorsal surface of PMA-treated macrophages. Circularized ruffles and macropinocytotic cups were also observed on some phenoxybenzamine + PMA-treated cells. Scale bar: 2 μm. (B) Bar graph shows quantification of membrane ruffles normalized to total cell number. Data represent the mean ± SEM. n = 5; * P < 0.05, significantly different from vehicle, # P < 0.05, significantly different from PMA by one-way ANOVA with Bonferroni post hoc test. (C) Macrophages were treated with vehicle, PMA or imipramine + PMA as described in (A) and fixed in 2% PFA. Nuclei were stained by Hoechst (blue) and F-actin was labelled by 488 phalloidin (green). Yellow arrows indicate membrane ruffle formation in PMA-treated cells. Images were taken with a Zeiss 780 confocal microscope (63×; scale bar: 5 μm). Similar results have been observed in six independent experiments.
(nLDL) via macropinocytosis, leading to significant cholesterol accumulation and foam cell formation (Kruth et al., 2002) . Importantly, this process may contribute to atherosclerosis, independent of the classical scavenger receptormediated lipid internalization pathways (Csanyi et al., 2017) . As shown in Figure 7C , pre-incubation of macrophages with imipramine inhibited PMA-induced intracellular lipid accumulation in macrophages following nLDL treatment. In summary, these results demonstrate that imipramine inhibits stimulated macropinocytosis in a range of different cell types and suggest its potential as a new pharmacological tool to elucidate more fully the role of macropinocytosis in pathological processes.
Discussion
Macropinocytosis is a highly conserved, actin-dependent endocytic process by which extracellular fluid and pericellular solutes are internalized into cells. In the past few years, evidence has been accumulating that increased rate of macropinocytosis contributes to various pathological processes, including cardiovascular disorders, cancer, allergic diseases, Alzheimer's disease and bacterial/viral infections (Kruth et al., 2005; Mercer and Helenius, 2009; Commisso et al., 2013; Tang et al., 2015) . Unfortunately, most currently available inhibitors of macropinocytosis have limited bioavailability (Smith and Smith, 1973) , inhibit other endocytic processes and have non-specific endocytosisindependent effects (Ivanov, 2008) . Although in recent years pharmacological inhibition of macropinocytosis has emerged as a promising concept for the treatment of various diseases, no efforts have been made prior to this study to identify macropinocytosis inhibitors suitable for clinical use.
Interestingly, a recent study using the Molecular Libraries Small Molecule Repository library identified two chemical compounds that inhibit virus-induced macropinocytosis (Anantpadma et al., 2016) . The ability of these compounds to inhibit phagocytosis or caveolin-mediated endocytosis and their pharmacological/safety profiles were not investigated. In the present study, we have utilized a commercially available library with compounds that are already used in the clinic for treatment of various diseases to identify low MW compounds that inhibit macropinocytosis. The advantage of such a screen is that the drugs have been already tested in humans (and animals) and the concentrations at which the drugs are toxic, their pharmacological profile and potential side effects are known. As such, these compounds are ideal candidates for in vitro and in vivo basic research use as well as drug repurposing. The primary screen identified 14 compounds that at~10 μM inhibited >95% of macropinocytotic solute internalization in macrophages. A series of secondary screens confirmed the inhibitory activity for nine of these 14 drugs that blocked both PMA-induced and M-CSF (physiological stimulator)-induced macropinocytosis in RAW cells. Of these hits, two compounds were eliminated due to their incomplete (~50%) inhibition of macropinocytosis in primary murine macrophages. In these experiments, inhibitory activities of identified compounds (~10 μM) were comparable to that of EIPA (25 μM) though at slightly lower concentrations. IC 50 values of identified inhibitors were in the 40-700 nM range, with the Identification of novel macropinocytosis inhibitors exception of vinblastine, which was effective at low pM concentrations. Thus, a total of seven drugs, namely, auranofin, flubendazole, imipramine, itraconazole, phenoxybenzamine, terfenadine and vinblastine, proceeded to the cytotoxicity and selectivity testing. Flubendazole was found to be cytotoxic after longer exposure times and eliminated. The remaining six compounds had no inhibitory activity against clathrin-mediated and caveolin-mediated endocytosis. Auranofin, itraconazole and terfenadine, on the other hand, inhibited phagocytosis. These three drugs, therefore, were excluded from further analysis. The microtubule inhibitor vinblastine was also excluded from further study as it is known to inhibit the cell cycle at low concentrations and have serious undesired side effects in vivo (Cariou et al., 2010) . Interestingly, the inhibitory effect of vinblastine on macropinocytosis supports the role of microtubule-mediated intracellular transport (i.e. cytosol to membrane) in macropinocytosis. Moreover, these findings raise the question whether the anti-cancer effect of vinblastine is also mediated, at least partially, through inhibition of macropinocytosis. In summary, the primary and secondary screens identified two compounds (imipramine and phenoxybenzamine) that inhibited macropinocytosis without exerting cytotoxic effects or inhibiting phagocytosis and clathrin-mediated and caveolin-mediated endocytosis. Next, we used scanning electron microscopy and confocal imaging to investigate which morphological step during macropinocytosis was inhibited by imipramine and phenoxybenzamine. Our results indicated that preincubation of macrophages with imipramine inhibits phorbol ester-stimulated membrane ruffle formation. Interestingly, only partial inhibition of membrane ruffling was observed following treatment with phenoxybenzamine, with the remaining ruffles capable of circularizing and forming cups. These results suggest that imipramine inhibits activation of signalling molecules involved in membrane ruffling, while phenoxybenzamine inhibits multiple signalling pathways mediating both early ruffle formation and plasma membrane activities downstream of cup formation (i.e. cup closure and/or macropinosome formation). Singla et al., 2018) . Based on these results, we propose that imipramine directly inhibits Nox2 activation (major source of O 2 ·À in macrophages) or acts as an antioxidant. It is, however, unknown whether a partial (50%) inhibition of O 2 ·À levels is sufficient to inhibit macropinocytosis. At present, the mechanism(s) by which imipramine inhibits macropinocytosis is unknown and requires further investigation. Pharmacological inhibition of NHE represents the most widely used and accepted method to investigate the role of macropinocytosis in endocytic processes in vitro as well as in the pathogenesis of disease development in vivo (Ivanov, 2008; Commisso et al., 2013) . As NHEs are ubiquitously expressed transmembrane proteins that regulate intracellular sodium concentration, cellular and body water homeostasis and potentially all pH sensitive signalling pathways, results especially from in vivo studies employing NHE blockers would require confirmation using alternative, more specific approaches. Importantly, our experiments demonstrated that imipramine does not inhibit NHE or regulate intracellular pH in macrophages. Other advantages of imipramine compared with currently used macropinocytosis inhibitors are its excellent bioavailability following p.o. administration (95%) and its relatively long biological half-life (~20 h) (Heck et al., 1979) . Introduced into medicine in the 1960s, imipramine was the first tricyclic antidepressant (TCA), a class named for its three-ring molecular structure. Imipramine inhibits reuptake of the neurotransmitters noradrenaline and 5-HT in the brain and blocks muscarinic cholinergic and dopamine receptors (Tatsumi et al., 1997) . These mechanisms must be considered when imipramine is used as a macropinocytosis inhibitor especially in in vivo experiments. With this said, we anticipate that structure-activity relationship studies using TCAs may yield novel compounds that maintain their inhibitory effect on macropinocytosis but exert no effect on neurotransmitter uptake or inhibit dopaminergic and muscarinic receptors. This is currently an area of active investigation in our laboratory. Taking this even further, an exciting area of research would be the conjugation of selective macropinocytosis inhibitors with 'homing' peptides to achieve tissue-specific inhibition of macropinocytosis (Ye and Yang, 2009) . Relevant to this, we showed that imipramine inhibits stimulated macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. Finally, an ideal macropinocytosis inhibitor would block only stimulated macropinocytosis as constitutive macropinocytosis is involved in the regulation of physiological processes (Sallusto et al., 1995; Liu and Roche, 2015) . Importantly, our scanning electron microscopy data on the quantification of the membrane ruffles suggest that imipramine does not inhibit constitutive membrane ruffling in macrophages.
In summary, we report here the development of a systematic screen designed to identify low MW inhibitors of macropinocytosis. By screening a library of 640 FDAapproved compounds, the primary screen and subsequent secondary analyses identified a low MW drug, imipramine, that blocked membrane ruffle formation and inhibited macropinocytosis in macrophages, dendritic cells and cancer cells. We anticipate that the identified macropinocytosis inhibitor will prove useful as a pharmacological tool to more fully explore the role of macropinocytosis in pathological processes. Our study also suggests that imipramine and Identification of novel macropinocytosis inhibitors potentially other TCAs might be good candidates for repurposing as therapeutic agents in pathological processes involving macropinocytosis and serve as a chemical platform for developing more specific inhibitors of macropinocytosis.
